Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 35711 | 4.54 |
09:34 ET | 901 | 4.51 |
09:36 ET | 6085 | 4.395 |
09:38 ET | 1400 | 4.37 |
09:39 ET | 6453 | 4.3501 |
09:41 ET | 12593 | 4.34 |
09:43 ET | 5723 | 4.38 |
09:45 ET | 301 | 4.38 |
09:48 ET | 2636 | 4.34 |
09:50 ET | 4482 | 4.36 |
09:56 ET | 3800 | 4.4099 |
09:57 ET | 230 | 4.4099 |
09:59 ET | 700 | 4.42 |
10:01 ET | 300 | 4.42 |
10:03 ET | 1000 | 4.42 |
10:06 ET | 3900 | 4.41 |
10:08 ET | 5138 | 4.395 |
10:10 ET | 818 | 4.4 |
10:12 ET | 800 | 4.39 |
10:14 ET | 4529 | 4.4 |
10:15 ET | 435 | 4.38 |
10:17 ET | 2275 | 4.395 |
10:19 ET | 10752 | 4.31 |
10:21 ET | 700 | 4.3105 |
10:24 ET | 651 | 4.315 |
10:26 ET | 900 | 4.32 |
10:28 ET | 400 | 4.31 |
10:30 ET | 2800 | 4.32 |
10:32 ET | 12700 | 4.295 |
10:33 ET | 17044 | 4.305 |
10:35 ET | 2681 | 4.305 |
10:37 ET | 3815 | 4.31 |
10:39 ET | 1859 | 4.31 |
10:42 ET | 2131 | 4.305 |
10:44 ET | 2700 | 4.3 |
10:46 ET | 6565 | 4.3 |
10:48 ET | 8056 | 4.302 |
10:50 ET | 1100 | 4.305 |
10:51 ET | 6442 | 4.304 |
10:53 ET | 800 | 4.3 |
10:55 ET | 21431 | 4.276 |
10:57 ET | 28467 | 4.285 |
11:00 ET | 26700 | 4.285 |
11:02 ET | 2280 | 4.275 |
11:04 ET | 10420 | 4.285 |
11:06 ET | 200 | 4.28 |
11:08 ET | 1967 | 4.3 |
11:09 ET | 100 | 4.295 |
11:11 ET | 500 | 4.295 |
11:13 ET | 57767 | 4.295 |
11:15 ET | 724 | 4.3 |
11:18 ET | 1300 | 4.29 |
11:20 ET | 6476 | 4.325 |
11:22 ET | 8185 | 4.29 |
11:24 ET | 3400 | 4.29 |
11:27 ET | 500 | 4.295 |
11:29 ET | 100 | 4.295 |
11:31 ET | 2939 | 4.3 |
11:33 ET | 100 | 4.295 |
11:36 ET | 4000 | 4.29 |
11:38 ET | 300 | 4.29 |
11:42 ET | 1965 | 4.29 |
11:44 ET | 5170 | 4.2802 |
11:45 ET | 10013 | 4.255 |
11:47 ET | 2900 | 4.2501 |
11:49 ET | 380 | 4.255 |
11:51 ET | 14329 | 4.26 |
11:54 ET | 2856 | 4.25 |
11:56 ET | 1321 | 4.24 |
11:58 ET | 2619 | 4.215 |
12:00 ET | 3690 | 4.215 |
12:02 ET | 8615 | 4.21 |
12:03 ET | 1900 | 4.215 |
12:05 ET | 200 | 4.22 |
12:07 ET | 100 | 4.21 |
12:09 ET | 1300 | 4.22 |
12:12 ET | 18281 | 4.2 |
12:14 ET | 4223 | 4.195 |
12:16 ET | 754 | 4.1999 |
12:18 ET | 13934 | 4.185 |
12:20 ET | 1250 | 4.19 |
12:21 ET | 6296 | 4.185 |
12:23 ET | 1855 | 4.175 |
12:25 ET | 56113 | 4.155 |
12:27 ET | 15646 | 4.1284 |
12:30 ET | 11157 | 4.125 |
12:32 ET | 15550 | 4.13 |
12:34 ET | 19739 | 4.13 |
12:36 ET | 5731 | 4.1261 |
12:38 ET | 6735 | 4.125 |
12:39 ET | 8700 | 4.125 |
12:41 ET | 123129 | 4.105 |
12:43 ET | 145898 | 4.0699 |
12:45 ET | 30386 | 4.0902 |
12:48 ET | 71830 | 4.0976 |
12:50 ET | 5518 | 4.075 |
12:52 ET | 8418 | 4.0799 |
12:54 ET | 15109 | 4.06 |
12:56 ET | 24520 | 4.135 |
12:57 ET | 5142 | 4.1391 |
12:59 ET | 9806 | 4.14 |
01:01 ET | 3148 | 4.14 |
01:03 ET | 3399 | 4.15 |
01:06 ET | 5451 | 4.17 |
01:08 ET | 1701 | 4.17 |
01:10 ET | 1150 | 4.165 |
01:12 ET | 5272 | 4.13 |
01:14 ET | 608 | 4.1264 |
01:15 ET | 11064 | 4.1 |
01:17 ET | 3393 | 4.1 |
01:19 ET | 416 | 4.105 |
01:21 ET | 350 | 4.1098 |
01:24 ET | 1319 | 4.105 |
01:26 ET | 8848 | 4.115 |
01:28 ET | 4843 | 4.105 |
01:30 ET | 8910 | 4.105 |
01:32 ET | 5049 | 4.095 |
01:33 ET | 5048 | 4.09 |
01:35 ET | 1200 | 4.095 |
01:37 ET | 5308 | 4.09 |
01:39 ET | 5839 | 4.082 |
01:42 ET | 6003 | 4.07 |
01:46 ET | 3729 | 4.0788 |
01:48 ET | 200 | 4.075 |
01:50 ET | 9043 | 4.07 |
01:51 ET | 12309 | 4.07 |
01:53 ET | 600 | 4.08 |
01:55 ET | 1275 | 4.07 |
01:57 ET | 9441 | 4.075 |
02:00 ET | 17963 | 4.075 |
02:02 ET | 7555 | 4.075 |
02:04 ET | 3400 | 4.075 |
02:06 ET | 6533 | 4.085 |
02:08 ET | 6459 | 4.0892 |
02:09 ET | 3300 | 4.0899 |
02:11 ET | 4599 | 4.0892 |
02:13 ET | 600 | 4.08 |
02:15 ET | 5753 | 4.085 |
02:18 ET | 5553 | 4.085 |
02:20 ET | 13273 | 4.07 |
02:22 ET | 300 | 4.065 |
02:24 ET | 203 | 4.065 |
02:26 ET | 600 | 4.065 |
02:27 ET | 13856 | 4.07 |
02:29 ET | 7619 | 4.06 |
02:31 ET | 24018 | 4.0494 |
02:33 ET | 1925 | 4.0492 |
02:36 ET | 4253 | 4.065 |
02:38 ET | 4745 | 4.0601 |
02:40 ET | 30659 | 4.1001 |
02:42 ET | 5834 | 4.105 |
02:44 ET | 5700 | 4.1 |
02:45 ET | 400 | 4.1 |
02:47 ET | 7000 | 4.055 |
02:49 ET | 4673 | 4.05 |
02:51 ET | 3079 | 4.04 |
02:54 ET | 5508 | 4.045 |
02:56 ET | 3000 | 4.045 |
02:58 ET | 6300 | 4.045 |
03:00 ET | 12716 | 4.05 |
03:02 ET | 1325 | 4.055 |
03:03 ET | 25717 | 4.075 |
03:05 ET | 35194 | 4.0598 |
03:07 ET | 1355 | 4.0599 |
03:09 ET | 11052 | 4.065 |
03:12 ET | 3805 | 4.065 |
03:14 ET | 340 | 4.07 |
03:16 ET | 2010 | 4.065 |
03:18 ET | 2697 | 4.06 |
03:20 ET | 8290 | 4.05 |
03:21 ET | 10646 | 4.04 |
03:23 ET | 3900 | 4.0491 |
03:25 ET | 67992 | 4.025 |
03:27 ET | 7541 | 4.025 |
03:30 ET | 5226 | 4.025 |
03:32 ET | 29755 | 4.01 |
03:34 ET | 31518 | 4.0001 |
03:36 ET | 95730 | 3.885 |
03:38 ET | 157730 | 3.955 |
03:39 ET | 42326 | 3.9509 |
03:41 ET | 18027 | 3.945 |
03:43 ET | 31023 | 3.935 |
03:45 ET | 19603 | 3.915 |
03:48 ET | 34930 | 3.92 |
03:50 ET | 33430 | 3.925 |
03:52 ET | 24336 | 3.925 |
03:54 ET | 85473 | 3.945 |
03:56 ET | 31038 | 3.965 |
03:57 ET | 44147 | 3.95 |
03:59 ET | 187810 | 3.95 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 692.3M | -12.0x | --- |
Immunome Inc | 948.3M | -2.7x | --- |
Oruka Therapeutics Inc | 906.5M | -4.4x | --- |
4D Molecular Therapeutics Inc | 856.5M | -7.3x | --- |
Perspective Therapeutics Inc | 884.7M | -9.6x | --- |
IGM Biosciences Inc | 939.6M | -4.8x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $692.3M |
---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-0.33 |
Book Value | $0.46 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 66.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.